Phoenix Biotechnology, Inc. (PBI)'s Focus
While the prevention and treatment of human malignant disease remains PBI's primary focus, novel, patented extracts of Nerium oleander continue to reveal promising avenues of research showing activity against certain viral and neurodegenerative diseases.
2011 and 2009 ASCO
"Poster Discussion Group"
2009 SIO Intl' Conference
"Best of SIO"
"Technology Super Star"
Currently 42 patients have been enrolled in our PBI-05204 Phase II clinical trial for treatment of Stage IV metastatic pancreatic cancer at five sites across the USA. The study is on hold to new patient accrual pending the first interim analysis of data anticipated for mid-July per FDA protocol requirements. Enrollment to date represents 85% of planned patient accrual.
The article titled "Pharmacokinetics and Comparative Effects of Frondosides in Pancreatic Cancer" by: Jasem Al Shemaili, Khatija Parekh, Robert Newman, Björn Hellman, Carl Woodward, Abdu Adem, Peter Collin, Thomas E Adrian is now published in Marine Drugs.